Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial

被引：0

作者：

Jin Li

Weijian Guo

Yuxian Bai

Yanhong Deng

Lei Yang

Zhendong Chen

Haijun Zhong

Ruihua Xu

Hongming Pan

Yongqian Shu

Ying Yuan

Jianfeng Zhou

Nong Xu

Tianshu Liu

Dong Ma

Changping Wu

Ying Cheng

Jianming Xu

Donghui Chen

Wei Li

Sanyuan Sun

Zhuang Yu

Peiguo Cao

Lin Shen

Haihui Chen

Shubin Wang

Hongbing Wang

Songhua Fan

Xiaojun Guo

Ning Wang

Rubing Han

Bin Zhang

Shukui Qin

机构：

[1] Tongji University East Hospital,Department of Medical Oncology

[2] Fudan University Shanghai Cancer Center,Department of Medical Oncology, Shanghai Medical College

[3] Harbin Medical University Cancer Hospital,Department of Medical Oncology

[4] The Sixth Hospital Affiliated to Sun Yat-sen University,Department of Medical Oncology

[5] Nantong Cancer Hospital,Department of Medical Oncology

[6] The Second Hospital of Anhui Medical University,Department of Medical Oncology

[7] Zhejiang Cancer Hospital,Department of Medical Oncology

[8] Sun Yat-sen University Cancer Center,Department of Medical Oncology

[9] Sir Run Run Shaw Hospital,Department of Medical Oncology

[10] Jiangsu Provincial Hospital,Department of Medical Oncology

[11] The Second Affiliated Hospital of Zhejiang University,Department of Medical Oncology

[12] Peking Union Medical College Hospital,Department of Oncology

[13] The First Affiliated Hospital Zhejiang University College of Medicine,Department of Medical Oncology

[14] Fudan University Zhongshan Hospital,Department of Medical Oncology

[15] Guangdong Provincial People’s Hospital,Department of Medical Oncology

[16] The First People’s Hospital of Changzhou,Department of Medical Oncology

[17] Jilin Province Cancer Hospital,Department of Medical Oncology

[18] The Fifth Medical Center of Chinese,Department of Medical Oncology

[19] PLA General Hospital,Department of Medical Oncology

[20] Shanghai Jiao Tong University Affiliated First People’s Hospital,Department of Medical Oncology

[21] The First Hospital of Jilin University,Department of Medical Oncology

[22] Xuzhou Central Hospital,Department of Medical Oncology

[23] The Affiliated Hospital of Medical College Qingdao University,Department of Medical Oncology, Xiangya Hospital of Central South University

[24] The Third Xiangya Hospital of Central South University,Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)

[25] Peking University Cancer Hospital & Institute,Department of Medical Oncology

[26] Liuzhou Worker’s Hospital,Department of Medical Oncology

[27] Beijing University ShenZhen Hospital,Department of Medical Oncology

[28] Beijing University,undefined

[29] The Affiliated Hospital of Xuzhou Medical College,undefined

[30] Xuzhou Medical College,undefined

[31] Hutchison MediPharma Limited,undefined

[32] Lilly China,undefined

[33] Drug Development and Medical Affairs Center,undefined

[34] Cancer Center of Jinling Hospital,undefined

来源：

Advances in Therapy | 2020年 / 37卷

关键词：

Adverse events of special interest; Chinese patients; FRESCO trial; Fruquintinib; Metastatic colorectal cancer; Safety profile;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：4585 / 4598

页数：13

共 50 条

[1] Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial
Li, Jin
Guo, Weijian
Bai, Yuxian
Deng, Yanhong
Yang, Lei
Chen, Zhendong
Zhong, Haijun
Xu, Ruihua
Pan, Hongming
Shu, Yongqian
Yuan, Ying
Zhou, Jianfeng
Xu, Nong
Liu, Tianshu
Ma, Dong
Wu, Changping
Cheng, Ying
Xu, Jianming
Chen, Donghui
Li, Wei
Sun, Sanyuan
Yu, Zhuang
Cao, Peiguo
Shen, Lin
Chen, Haihui
Wang, Shubin
Wang, Hongbing
Fan, Songhua
Guo, Xiaojun
Wang, Ning
Han, Rubing
Zhang, Bin
Qin, Shukui
ADVANCES IN THERAPY, 2020, 37 (11) : 4585 - 4598
[2] Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study
Eng, Cathy
Dasari, Arvind
Lonardi, Sara
Garcia-Carbonero, Rocio
Elez, Elena
Yoshino, Takayuki
Sobrero, Alberto F.
Yao, James C.
Garcia-Alfonso, Pilar
Kocsis, Judit
Cubillo, Antonio
Sartore-Bianchi, Andrea
Satoh, Taroh
Randrian, Violaine
Tomasek, Jiri
Chong, Geoff
Yang, Zhao
Guevara, Ferdinand M.
Schelman, William R.
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in FRESCO trial
Qin, Shukui
Li, Jin
Bai, Yuxian
Deng, Yanhong
Yang, Lei
Xu, Rui-Hua
Zhong, Haijun
Chen, Zhendong
Pan, Hongming
Guo, Weijian
Shu, Yongqian
Xu, Jianming
Peng, Cike
Chen, Yun
Li, Hongyan
Wang, Ning
Guo, Xiaojun
Peng, Mengye
Fan, Songhua
Shen, Lin
FUTURE ONCOLOGY, 2021, 17 (15) : 1923 - 1931
[4] Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial
Li, Jin
Qin, Shukui
Xu, Rui-Hua
Shen, Lin
Xu, Jianming
Bai, Yuxian
Yang, Lei
Deng, Yanhong
Chen, Zhen-dong
Zhong, Haijun
Pan, Hongming
Guo, Weijian
Shu, Yongqian
Yuan, Ying
Zhou, Jianfeng
Xu, Nong
Liu, Tianshu
Ma, Dong
Wu, Changping
Cheng, Ying
Chen, Donghui
Li, Wei
Sun, Sanyuan
Yu, Zhuang
Cao, Peiguo
Chen, Haihui
Wang, Jiejun
Wang, Shubin
Wang, Hongbing
Fan, Songhua
Hua, Ye
Su, Weiguo
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (24): : 2486 - 2496
[5] Fruquintinib for patients with metastatic colorectal cancer previously treated with standard treatments
Quesada, Stanislas
Chatelet, Chloe
BULLETIN DU CANCER, 2024, 111 (12) : 1084 - 1085
[6] Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2
Eng, Cathy
Dasari, Arvind
Lonardi, Sara
Garcia-Carbonero, Rocio
Elez, Elena
Yoshino, Takayuki
Sobrero, Alberto
Yao, James
Garcia-Alfonso, Pilar
Kocsis, Judit
Gracian, Antonio Cubillo
Sartore-Bianchi, Andrea
Satoh, Taroh
Randrian, Violaine
Tomasek, Jiri
Chong, Geoff
Yang, Zhao
Guevara, Ferdinand
Schelman, William
Pallai, Rajash
Tabernero, Josep
ONCOLOGIST, 2025, 30 (03):
[7] Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 trial
Garcia-Carbonero, R.
Dasari, N. A.
Eng, C.
Tabernero, J.
Yoshino, T.
Hochster, H.
Arnold, D.
Randrian, V.
Schelman, W.
Dong, L.
Yu, Z.
Chen, L.
Lonardi, S.
ANNALS OF ONCOLOGY, 2024, 35 : S439 - S439
[8] Efficacy and safety of fruquintinib across different subgroups of patients with previously treated metastatic colorectal cancer: A meta-analysis
Da Silva, Luis Felipe Leite
Peixoto, Renata D'Alpino
Binbin, Zheng-Lin
De Menezes, Junior Alonso
Batalini, Felipe
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] FRESCO-2: A global/multiregional phase III clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with metastatic colorectal cancer
Yoshino, T.
Dasari, N. A.
Lonardi, S.
Garcia-Carbonero, R.
Elez Fernandez, M. E.
Sobrero, A.
Yao, J. C.
Garcia Alfonso, P.
Kocsis, J.
Cubillo Gracian, A.
Bianchi, A. Sartore
Randrian, V.
Tomasek, J.
Chong, G.
Yang, Z.
Schelman, W.
Kania, M.
Tabernero, J.
Eng, C.
Satoh, T.
ANNALS OF ONCOLOGY, 2022, 33 : S1446 - S1447
[10] FRESCO-2: A global phase 3 multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients (pts) with refractory metastatic colorectal cancer (mCRC)
Arnold, Dirk
Dasari, Arvind
Lonardi, Sara
Garcia-Carbonero, Rocio
Fernandez, Maria Elena Elez
Yoshino, Takayuki
Sobrero, Alberto F.
Yao, James C.
Alfonso, Pilar Garcia
Kocsis, Judit
Gracian, Antonio Cubillo
Satore-Bianchi, Andrea
Satoh, Taroh
Randrian, Violaine
Tomasek, Jiri
Chong, Geoffrey
Yang, Zhao
Shelman, William
Kania, Marek
Tabernero, Josep
Eng, Cathy
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 56 - 57

← 1 2 3 4 5 →